TY - JOUR
T1 - Diphtheria-toxin-interleukin-3 fusion protein (DT388IL3) prolongs disease-free survival of leukemic immunocompromised mice
AU - Black, J. H.
AU - McCubrey, J. A.
AU - Willingham, M. C.
AU - Ramage, J.
AU - Hogge, D. E.
AU - Frankel, A. E.
N1 - Funding Information:
This work was su pported by grants from the Leukemia and Lymphoma Society (Grant No. 6114–99), NIH (Grant No. R01CA76178, R21CA90550, and R01CA90263) to A Frankel, and from the Cancer Research Society of Canada and the National Cancer Institute of Canada to D Hogge.
PY - 2003/1/1
Y1 - 2003/1/1
N2 - The novel fusion protein DT388IL3, composed of the catalytic and translocation domains of diphtheria toxin (DT388) fused with a Met-His linker to human interleukin 3 (IL-3), was tested for anti-leukemia efficacy in an in vivo model of differentiated human acute myeloid leukemia (AML). Six-week-old female SCID mice were irradiated with 350 cGy, inoculated 24 h later with 20 million (i.v., i.p., or s.c.) TF1 cells transfected with the v-SRC oncogene, and treated i.p., starting 24 h later, with up to five daily injections of saline, DT388IL3 (2 μg), DT388GMCSF (2 μg), DAB389IL2 (2 μg), or cytarabine (80 μg) or two weekly injections of anti-CD33-calicheamicin conjugate (5 μg). Animals were monitored twice daily, and moribund animals killed and necropsied. Control animals had a median disease-free survival (DFS) of 37 days (i.v., n = 45), 35 days (i.p., n = 20), and 21 days (s.c., n = 20), respectively. Only 5/49 (10%) of the DT388IL3 treated i.v. inoculated animals died with leukemia. Median DFS with i.v., i.p. and s.c. tumor inoculated animals was prolonged by fusion protein treatment to >120 days, 66 days and 31 days (P < 0.001, = 0.0003, and = 0.0006), respectively. Median DFS with s.c. tumor inoculated animals was also prolonged by other active anti-leukemia agents (DT388GMCSF, cytarabine and anti-CD33-calicheamicin) relative to controls by 67%, 172% and 47% (P < 0.0001, <0.0001, and =0.0004), respectively. In contrast, median DFS with s.c. tumor inoculated animals treated with DAB389IL2 non-significantly reduced by 13% relative to controls (P = 0.21). Thus, DT388IL3 fusion protein demonstrates in vivo anti-leukemia efficacy and warrants further preclinical development for treatment of chemoresistant, IL-3 receptor positive AML patients.
AB - The novel fusion protein DT388IL3, composed of the catalytic and translocation domains of diphtheria toxin (DT388) fused with a Met-His linker to human interleukin 3 (IL-3), was tested for anti-leukemia efficacy in an in vivo model of differentiated human acute myeloid leukemia (AML). Six-week-old female SCID mice were irradiated with 350 cGy, inoculated 24 h later with 20 million (i.v., i.p., or s.c.) TF1 cells transfected with the v-SRC oncogene, and treated i.p., starting 24 h later, with up to five daily injections of saline, DT388IL3 (2 μg), DT388GMCSF (2 μg), DAB389IL2 (2 μg), or cytarabine (80 μg) or two weekly injections of anti-CD33-calicheamicin conjugate (5 μg). Animals were monitored twice daily, and moribund animals killed and necropsied. Control animals had a median disease-free survival (DFS) of 37 days (i.v., n = 45), 35 days (i.p., n = 20), and 21 days (s.c., n = 20), respectively. Only 5/49 (10%) of the DT388IL3 treated i.v. inoculated animals died with leukemia. Median DFS with i.v., i.p. and s.c. tumor inoculated animals was prolonged by fusion protein treatment to >120 days, 66 days and 31 days (P < 0.001, = 0.0003, and = 0.0006), respectively. Median DFS with s.c. tumor inoculated animals was also prolonged by other active anti-leukemia agents (DT388GMCSF, cytarabine and anti-CD33-calicheamicin) relative to controls by 67%, 172% and 47% (P < 0.0001, <0.0001, and =0.0004), respectively. In contrast, median DFS with s.c. tumor inoculated animals treated with DAB389IL2 non-significantly reduced by 13% relative to controls (P = 0.21). Thus, DT388IL3 fusion protein demonstrates in vivo anti-leukemia efficacy and warrants further preclinical development for treatment of chemoresistant, IL-3 receptor positive AML patients.
KW - Acute myeloid leukemia
KW - Diphtheria toxin
KW - Fusion toxin
KW - Interleukin-3
UR - http://www.scopus.com/inward/record.url?scp=0037262225&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037262225&partnerID=8YFLogxK
U2 - 10.1038/sj.leu.2402744
DO - 10.1038/sj.leu.2402744
M3 - Article
C2 - 12529673
AN - SCOPUS:0037262225
SN - 0887-6924
VL - 17
SP - 155
EP - 159
JO - Leukemia
JF - Leukemia
IS - 1
ER -